Nurix Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 27.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 2.96B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials f...